Key Takeaways
- Challenging quarter, H2 recovery bet: Both crop protection and pharma divisions faced severe demand headwinds from global destocking and Chinese competition, but management expects a stepwise recovery starting H2 FY24 as channel inventories normalize.
- Margins defended by lower input costs: Softening raw material prices partially offset volume and pricing pressure, with gross margins actually improving YoY; the full benefit of lower-cost inventory is expected to flow through from late Q2/Q3.
- New project margins targeted at 24-25% EBITDA: Legacy products drag the blended margin to ~20%, but all new projects are being priced for structurally higher returns, and the mix shift toward new products is accelerating.
- Capacity build-out continues despite the cycle: The Panoli multipurpose plant and a dedicated animal health facility are commissioning now, with validation batches starting Q3/Q4; these assets are positioned for the next demand upcycle.
- What to watch next quarter: Whether CDMO and crop inventory normalization actually begins by end-Q3 as guided, the pace of new product launches (3-4 targeted by FY24-end), and any permanent revocation of the Panoli GPCB closure notice.
Demand Environment & Volume Headwinds
- Crop protection destocking: Global distributors and end customers are aggressively drawing down high channel inventories built during the supply-constrained period, compressing volumes and exposing Hikal to aggressive price competition from Chinese exporters. The situation is expected to normalize only toward the end of this calendar year.
- Pharma CDMO inventory overhang: Reduced demand from CDMO customers reflects their own high channel inventory, not a loss of contracts; the company signed a few new CDMO contracts in the quarter and expects normalization toward the end of FY24.
- API market pressure: Intense competition and high-cost inventory in the channel pipeline are creating pricing pressure, though the company has maintained market share in legacy products and sees the US generic market improving sequentially.
- China competition asymmetry: Chinese competition is far more severe on the crop side than pharma, with significant new capacity being built in China for crop protection chemicals; management expects this to normalize in one to two quarters as end-product demand picks up toward Q3.
- Sequential recovery logic: Q1 is historically the slowest quarter due to annual maintenance shutdowns, and every year follows a stepwise quarter-on-quarter improvement pattern; management insists Q4-to-Q1 comparison is not the correct lens.
Hiremath: "If you look at historically, our quarter one is always our slowest quarter because we take our annual maintenance shutdowns. And this is a time every year our quarter one is our slowest and we always have a sequential step wise improvement quarter-on-quarter, and this year is no different."
Margin Trajectory & Operating Leverage
- Gross margin improvement despite revenue decline: Softening raw material prices have driven gross margins higher compared to the same period last year, even as finished good prices fell faster; raw material prices are near their lowest levels.
- Fixed cost structure creates H2 leverage: Costs are largely fixed, so the expected H2 volume recovery will translate directly into EBITDA margin expansion through operating leverage; utilization is currently at 65-75% against a normal 80-85%.
- New vs legacy margin bifurcation: New projects and products are being contracted at 24-25% EBITDA margins, while legacy products drag the blended margin to approximately 20%; dependency on old contracts is declining year-on-year as they are phased out or replaced.
- Long-term margin ambition: Management expects a significant uptick in margins over the next four to five years as volumes increase and operating leverage kicks in, with existing gross block returning to 18-19% and new projects coming on stream at 22-24% from next year.
- Raw material lag effect: The benefit of lower raw material prices will start flowing through from the end of Q2 or early Q3, as older higher-cost inventories are converted to finished goods and sold through.
Hiremath: "If you look at the pharma business for the new projects and the new products, we're getting closer to the 24%-25% up of EBITDA level, my obviously particular blend because of a legacy for us it may come down to 20% odd as a blended. So, our aim is for any new project, we're targeting 24%-25% EBITDA. And obviously, we'll strive for even better."
Capacity Expansion & New Projects
- Panoli multipurpose plant: The plant is approaching completion and commissioning has begun; it is currently in the stabilization phase and proceeding according to schedule. Separately, the Panoli API facility received a No Action Indicated (NAI) compliance status with zero 483 observations from the US FDA.
- Animal health dedicated facility: A new multipurpose facility for animal health is on track and undergoing commissioning; validation batches of products under development will be provided to the customer during the next few quarters as a first step toward commercialization.
- Dedicated capacity model: Two years ago, Hikal signed a major long-term contract with a client, setting up a large dedicated facility for multiple products in animal health; similar opportunities are being pursued in human health and crop protection.
- New product pipeline: A robust pipeline of 8 to 10 products is under development, with a target to launch 3 to 4 products by the end of FY24; two Phase 3 clinical trial opportunities are progressing as planned and likely to become commercial in upcoming years.
- Utilization ramp timeline: New capacities on the animal health and crop side will start adding to revenues and margins from Q3-Q4 onwards, with validation quantities beginning in the same window; peak utilization for new capacity will take three to four years.
Regulatory & Operational Updates
- Panoli GPCB closure notice resolved: On 22 July 2023, GPCB directed Hikal to cease operations at Panoli within 15 days, citing technical violations related to a product manufactured in early 2021 during COVID. The company clarified the matter, and GPCB revoked the closure direction for an initial three months; the facility continues to operate normally with no interruption, and permanent revocation is expected.
- US FDA audit success: The API facility at Panoli received NAI compliance status with zero 483 observations, reinforcing the site's quality standing with a key regulator.
- Project Pinnacle launched: Several initiatives have commenced spanning customer centricity augmentation, ESG benchmarking and integration, and efficiency enhancement across manufacturing, supply chain and operations.
Strategic Positioning & Long-Term Bets
- China-plus-one intact: Management affirmed the strategy remains very much in place, with new enquiries and new customers continuing to come on board despite the current pricing pressure from Chinese exporters.
- 2030 ambition: The company targets significantly higher than ₹6,000 crore in sales by 2030 with 25% margins; the ₹3,000 crore milestone is "a few more years from now," with peak utilization of new capacity taking three to four years.
- Dedicated capacity replication: The animal health dedicated-capacity model, where a large facility is built for a single client with multiple products under a long-term contract, is being actively replicated in human health and crop protection.
Hiremath: "I am not even talking of 10 years, I am talking of next four to five years, we will see a significant uptick in margins, and the operating leverage kicking in as volumes increase."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pharma demand normalization | CDMO and API demand returns to normal as channel inventory clears | Next 1-2 quarters (by end-FY24) |
| Crop inventory normalization | Distributor/end-customer destocking ends, demand and prices normalize | End of calendar 2023 / Q3-Q4 FY24 |
| Volume recovery | Volumes pick up, driving operating leverage and EBITDA improvement | H2 FY24 onwards |
| New product launches | 3-4 new products launched from a pipeline of 8-10 under development | By end of FY24 |
| Validation batches (animal health) | Validation quantities provided to customer from new dedicated facility | Q3-Q4 FY24 |
| Capacity utilization | Utilization returns from 65-75% to 80-85% | H2 FY24 |
| Raw material margin benefit | Lower-cost inventory flows through to finished goods, improving margins | End of Q2 / early Q3 FY24 |
| New project EBITDA margin | All new projects and products contracted at 24-25% EBITDA | Ongoing (from now) |
| Blended margin recovery | Existing gross block returns to 18-19% EBITDA; new projects lift blended toward 20% | Next 2 years |
| Panoli GPCB permanent revocation | Permanent revocation of closure direction after initial 3-month period | Within 3 months (by Oct 2023) |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹388 cr, +2.4% YoY; -29% QoQ |
| EBITDA | ₹50 cr |
| EBITDA margin | 12.9% |
| Pharma revenue | ₹225 cr |
| Pharma EBIT margin | 4.4% |
| Crop protection revenue | ₹163 cr |
| Crop protection EBIT margin | 10.5% |
| Volume change | -13% YoY; -26% QoQ |
| Pharma capacity utilization | 70%-75%, vs historical 80%-85% |
| Crop protection capacity utilization | mid-60s%, vs historical 80%-85% |
| Term loans | ₹550 cr |
| Working capital debt | ₹240 cr |
| Cost of funds | 8.5%, blended short and long term |
| Capital work-in-progress | ₹400-460 cr as of June 30, 2023 |
| FY24 capex plan | ₹200 cr, 50:50 internal accruals and borrowings |